Call: 954-398-4474

Nevro’s HFX Spinal Cord Stimulation relieves diabetic neuropathy pain.

Nevro's HFX Spinal Cord Stimulation


A recent two-year study has unveiled the impressive efficacy of Nevro’s HFX spinal cord stimulator in providing enduring pain relief, enhancing the quality of life, and improving sleep for individuals battling painful diabetic neuropathy. This groundbreaking research offers hope to those affected by diabetic peripheral neuropathy (DPN), a challenging complication of diabetes.

Read Guide about Wegovy Dosage Guide: The Best Way For Weight Loss

Understanding Painful Diabetic Neuropathy:

Painful diabetic neuropathy (DPN) arises from nerve damage in the extremities, such as the hands and feet, due to high blood sugar levels. DPN symptoms encompass numbness, tingling, and, for some, excruciating pain. Traditional treatments primarily rely on medication, leaving room for newer spinal cord stimulation (SCS) devices to offer prolonged pain relief with fewer side effects.

Nevro’s HFX Spinal Cord Stimulation Device: A Game-Changer:

Nevro’s HFX is a high-frequency spinal cord stimulation (SCS) system specifically designed to alleviate painful DPN. It secured FDA approval in 2021 as the first of its kind. Several other SCS systems, including Medtronic’s Intellis and Vanta, and DyAnsys’ noninvasive First Relief, have since gained approval for managing painful DPN. Fill out this form to check if you or a friend qualify for CGMs and improve diabetes control.

Personal Testimony:

Alice Ortiz, a type 2 diabetes patient managing a 10-acre farm, has experienced a life-changing transformation through SCS devices. Nevro’s HFX not only relieved pain in her legs but also reduced lower back pain. Before discovering HFX, Ortiz struggled with various medications, each with limited pain relief and numerous side effects, hindering her ability to enjoy her hobbies and family activities.

Must Read CGMs in noncritical care hospitals optimizes glycemic control

The Study’s Impact:

Funded by Nevro, the study included 216 participants with painful DPN who had previously not responded to standard medication treatments. The results were remarkable, with an average reduction of 80% in lower limb pain. Over 90% of patients experienced more than 50% pain relief, in addition to improved quality of life and sleep.

Enhanced Functionality and Mobility:

Furthermore, the SCS device led to enhanced sensory, motor, and reflex functions, empowering individuals with DPN to engage in exercise, and potentially aiding in blood sugar and weight management. Safety concerns were minimal, with no neurological damage attributed to SCS.

Also, read about Omnipod 5

Medicare’s Expanded Coverage:

The Centers for Medicare and Medicaid Services (CMS) expanded SCS device coverage in July 2023, extending access to these treatments across all 50 states. This change has brought hope to approximately 11 million people, offering an improved quality of life through effective pain relief.

Considering HFX: A Trial Opportunity:

Nevro offers a week-long trial period for individuals interested in HFX, ensuring it is a suitable therapy for them. Before embarking on any new treatment for painful diabetic neuropathy, it is essential to consult with a healthcare professional to determine the best course of action.